logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Metastatic colorectal cancer: two regimens improve survival in patients with BRAF mutations.

Targeted regimens set to become new standard of care in previously treated patients.